Applied Health Economics and Health Policy This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Authors ’ Reply to Gandjour: “10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?”
(Source: Applied Health Economics and Health Policy)
Source: Applied Health Economics and Health Policy - December 2, 2023 Category: Health Management Source Type: research

Cost Effectiveness of Deep Brain Stimulation for Parkinson ’s Disease: A Systematic Review
ConclusionsThe cost effectiveness of DBS for PD varies by time horizon, costs considered, threshold utilized, and stage of PD progression. Standardizing approaches and comparing DBS with other treatments are needed for future research on effective PD management. (Source: Applied Health Economics and Health Policy)
Source: Applied Health Economics and Health Policy - November 28, 2023 Category: Health Management Source Type: research

Adding a Gene Expression Profile Test to Aid Differential Diagnosis and Treatment in Aggressive Large B-Cell Lymphoma: An Early Exploratory Economic Evaluation
ConclusionsOur estimates show that the combined test has a high probability of being cost effective. There is good quality evidence for the benefit of subtyping DLBCL but the evidence on the number of patients reclassified to or from BL and PMBCL and the impact of a more precise diagnosis and the cost of treatment is weak. The developers can use the price estimate to inform a return on investment calculations. Evidence will be required of how well the TempO-Seq® technology performs compared to the testing GEP technology used for subtyping in the recent clinical trial. For BL and PMBCL elements of the test, evidence would ...
Source: Applied Health Economics and Health Policy - November 28, 2023 Category: Health Management Source Type: research

Health Service Utilisation of People Living with Psychosis: Validity of Self-report Compared with Administrative Data in a Randomised Controlled Trial
ConclusionDespite poor agreement, when measuring visits to psychologists and other health professionals, small overall differences in group mean number of visits indicate that self-reported data may still be valid for use in economic evaluations in people living with psychosis. (Source: Applied Health Economics and Health Policy)
Source: Applied Health Economics and Health Policy - November 21, 2023 Category: Health Management Source Type: research

Local Level Economic Evaluation: What is it? What is its value? Is it Sustainable?
AbstractIn Australia, local health services with allocated budgets manage public hospital services for defined geographical areas. The authors were embedded in a local health service for around 2 years and undertook a range of local level economic evaluations for which three decision contexts were defined: intervention development, post-implementation and prioritisation. Despite difficulties in estimating opportunity costs and in the relevance of portfolio-based prioritisation approaches, economic evaluation added value to local decision-making. Development-focused (ex ante) economic evaluations used expert elicitation and...
Source: Applied Health Economics and Health Policy - November 18, 2023 Category: Health Management Source Type: research

Comment on: “The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022”
(Source: Applied Health Economics and Health Policy)
Source: Applied Health Economics and Health Policy - November 16, 2023 Category: Health Management Source Type: research

Societal Cost of Racial Pneumococcal Disease Disparities in US Adults Aged 50 Years or Older
ConclusionsUS societal cost of racial pneumococcal disease disparities in persons aged ≥ 50 years is substantial. Successful pneumococcal vaccination policy and programmatic interventions to mitigate these disparities could decrease costs and improve health. (Source: Applied Health Economics and Health Policy)
Source: Applied Health Economics and Health Policy - November 15, 2023 Category: Health Management Source Type: research

Use of Health Technology Assessment for the Continued Funding of Health Technologies: The Case of Immunoglobulins for the Management of Multifocal Motor Neuropathy
ConclusionsBeyond the ICER framework, other factors were acknowledged, including the high clinical need in a patient population for which there are no other active treatments available. This case study highlights the challenges of conducting HTA for already funded interventions, and the efficiency trade-offs required to fund effective high-cost therapies in rare conditions. (Source: Applied Health Economics and Health Policy)
Source: Applied Health Economics and Health Policy - November 11, 2023 Category: Health Management Source Type: research

Exploratory Approach to Incorporating Carbon Footprint in Health Technology Assessment (HTA) Modelling: Cost-Effectiveness Analysis of Health Interventions in the United Kingdom
ConclusionThis study illustrates a case study for estimating the effect of health policies on carbon emissions and provides a quantitative measure for obesity-related treatment decisions. (Source: Applied Health Economics and Health Policy)
Source: Applied Health Economics and Health Policy - November 10, 2023 Category: Health Management Source Type: research

Modelling Informal Carers ’ Health-Related Quality of Life: Challenges for Economic Evaluation
AbstractThere has been increasing interest in including carers ’ health-related qualify of life (HRQoL) in decision models, but currently there is no best practice guidance as to how to do so. Models thus far have typically assumed that carers’ HRQoL can be predicted from patient health states, as we illustrate with three examples of disease-modifying treat ments. However, this approach limits the mechanisms that influence carers’ HRQoL solely to patient health and may not accurately reflect carers’ outcomes. In this article, we identify and discuss challenges associated with modelling intervention effects on carer...
Source: Applied Health Economics and Health Policy - November 10, 2023 Category: Health Management Source Type: research

Cost-Effectiveness of the Second COVID-19 Booster Vaccination in the USA
ConclusionThe second booster strategy was likely to be dominant in reducing the disease burden of the COVID-19 pandemic. Expanding the second booster strategy to ages 18 –49 and 12–17 years would remain dominant due to their social contacts with the older age group. (Source: Applied Health Economics and Health Policy)
Source: Applied Health Economics and Health Policy - November 1, 2023 Category: Health Management Source Type: research

Methods for Economic Evaluations of Novel Oral Anticoagulants in Patients with Atrial Fibrillation: A Systematic Review
ConclusionNOACs may be more cost-effective than VKAs in patients with AF, but this conclusion applies to high-income countries, whereas VKAs may be more cost-effective in middle- and low-income countries. The reporting quality of included studies was variable, and certain methodological issues were presented. This study highlights the economic evaluation methodology of NOACs in patients with AF and provides recommendations for modeling methods and future studies. (Source: Applied Health Economics and Health Policy)
Source: Applied Health Economics and Health Policy - October 29, 2023 Category: Health Management Source Type: research

Adding Value to CHEERS: New Reporting Standards for Value of Information Analyses
(Source: Applied Health Economics and Health Policy)
Source: Applied Health Economics and Health Policy - October 25, 2023 Category: Health Management Source Type: research

Different Frameworks, Similar Results? Head-to-Head Comparison of the Generic Preference-Based Health-Outcome Measures CS-Base and EQ-5D-5L
ConclusionsThis study demonstrated that CS-Base and 5D-4L, which are grounded in the multi-attribute preference response framework, produced statistically robust coefficients, with better face validity than those for the EQ-5D-5L. CS-Base and the EQ-5D-5L outperformed the 5D-4L in differentiating between health states. Notwithstanding differences in content, measurement frameworks, and estimated coefficients, the computed health-state values were similar between CS-Base and EQ-5D-5L. (Source: Applied Health Economics and Health Policy)
Source: Applied Health Economics and Health Policy - October 12, 2023 Category: Health Management Source Type: research

Challenges in the Evaluation of Emerging Highly Specialised Technologies: Is There a Role for Living HTA?
AbstractThere is currently deep uncertainty about the clinical benefits and cost effectiveness of highly specialised technologies (HSTs), like gene and cell therapies. These treatments are novel, typically have high upfront costs, the patient populations are small and heterogenous, there is minimal information on their long-term safety and effectiveness, and data are limited and often of poor quality. With the increasing number of these technologies and their high cost burden on governments and health care providers, policy makers are currently walking a decision tightrope. On the one hand, an unfavourable funding decision...
Source: Applied Health Economics and Health Policy - October 12, 2023 Category: Health Management Source Type: research